Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+44-20-34576900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees50
OptionableNot Optionable
Silence Therapeutics (LON:SLN) Frequently Asked Questions
What is Silence Therapeutics' stock symbol?
Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."
How were Silence Therapeutics' earnings last quarter?
What price target have analysts set for SLN?
0 brokers have issued 12 month price targets for Silence Therapeutics' shares. Their forecasts range from GBX 277 to GBX 277. On average, they anticipate Silence Therapeutics' stock price to reach GBX 277 in the next year. This suggests a possible upside of 431.7% from the stock's current price. View Analyst Price Targets for Silence Therapeutics.
Has Silence Therapeutics been receiving favorable news coverage?
Headlines about SLN stock have trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Silence Therapeutics earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Silence Therapeutics' key competitors?
Some companies that are related to Silence Therapeutics include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AorTech International (AOR), Arix Bioscience (ARIX), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Biocure Technology (CURE), Biotest (BIO), Bioventix (BVXP) and BTG (BTG).
What other stocks do shareholders of Silence Therapeutics own?
Who are Silence Therapeutics' key executives?
Silence Therapeutics' management team includes the folowing people:
- Dr. David Horn Solomon, CEO & Director (Age 59)
- Dr. Rob Quinn, Interim CFO & Company Sec.
- Dr. Mark Cameron, Head of Chemistry
- Mr. Richard Jenkins, Head of Clinical Devel.
How do I buy shares of Silence Therapeutics?
Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Silence Therapeutics' stock price today?
One share of SLN stock can currently be purchased for approximately GBX 52.10.
What is Silence Therapeutics' official website?
How can I contact Silence Therapeutics?
Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.
MarketBeat Community Rating for Silence Therapeutics (LON SLN)
MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe SLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
